PARIS ( TheStreet) -- Sanofi ( SNY) extended its offer of $69 a share, or $18.5 billion, for Genzyme ( GENZ) to Feb. 15.

The tender offer was previously scheduled to expire last Friday, Jan. 21. All terms and conditions of the tender offer remain unchanged, Sanofi said in a statement Monday.

Sanofi, the French drugs giant, said it and Genzyme are discussing the structure of a contingent value right involving Genzyme's Lemtrada, a multiple sclerosis drug, as part of any transaction. Sanofi said "significant differences" remain on the potential contingent value right.

Sanofi said as of Jan. 21, about 0.4% of Genzyme's shares has been tendered.

Shares of Genzyme, the U.S. biotechnology company, closed Friday at $71.58.

-- Written by Joseph Woelfel

>To contact the writer of this article, click here: Joseph Woelfel

>To submit a news tip, send an email to: tips@thestreet.com.

If you liked this article you might like

Generic Drug Makers Hurt By Latest Federal Government Budget

Generic Drug Makers Hurt By Latest Federal Government Budget

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Investors Are Trying to Figure Out the 'Powell Put'

Investors Are Trying to Figure Out the 'Powell Put'

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know